Online inquiry

IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9675MR)

This product GTTS-WQ9675MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD19&CD3E gene. The antibody can be applied in Acute lymphocytic leukemia (ALL), Follicular lymphoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001178098.2; NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930; 916
UniProt ID P15391; P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ9675MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3056MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ5531MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ6239MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CR57
GTTS-WQ12761MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ13148MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04383119
GTTS-WQ2395MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 110
GTTS-WQ7403MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GA201
GTTS-WQ8484MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA hu1124
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW